Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
04/12/2023 - 07:00 AM
Conference call and webcast to take place on Friday, May 5, 2023 , at 8:30 a.m. ET
SAN DIEGO and CALGARY, AB April 12, 2023 ® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Friday, May 5, 2023 , at 8:30 a.m. ET to discuss a corporate update and financial results for the first quarter 2023.
Conference Call & Webcast Date: Friday, May 5, 2023Time: 8:30 a.m. ETDial In – North American Toll-Free: (888) 664-6383Dial In – International: (416) 764-8650RapidConnect: to join the conference call without operator assistance, please click here Conference ID (if needed): 3550-3191Webcast: please click here
A webcast of the call will also be available on the Investor Relations page of Oncolytics' website, available by clicking here , and will be archived for three months. A dial in replay will be available for one week and can be accessed by dialing (888) 390-0541 (North America ) or (416) 764-8677 (International) and using replay code: 503-191#.
About Oncolytics Biotech Inc.
Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Oncolytics is currently conducting and planning clinical trials evaluating pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies as it advances towards registration studies in metastatic breast cancer and pancreatic cancer. For further information, please visit: www.oncolyticsbiotech.com .
Logo: https://mma.prnewswire.com/media/1808285/3981527/Oncolytics_Biotech_Grey.jpg
https://www.prnewswire.com/news-releases/oncolytics-biotech-to-host-conference-call-to-discuss-first-quarter-financial-results-and-recent-operational-highlights-301795286.html
SOURCE Oncolytics Biotech® Inc.
ONCY Rankings
#846 Ranked by Stock Gains
ONCY Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
Tags
Health Technology, Biotechnology
About ONCY
oncolytics biotech is a biotechnology company focused on the development of oncolytic viruses as potential therapeutics for use in a broad range of cancers. the company is conducting clinical studies using reolysin®, its proprietary formulation of the human reovirus, in some of the most prevalent forms of the disease including lung, colorectal and pancreatic cancers. oncolytics’ clinical program includes a number of human trials at a variety of stages including a phase iii trial in head and neck cancers. the company has advanced its product manufacturing and intellectual property initiatives in parallel with its clinical development program to support development of a commercial product.
